LEADER 04294nam 22008415 450 001 9910298494303321 005 20200918224952.0 010 $a3-319-10536-1 024 7 $a10.1007/978-3-319-10536-9 035 $a(CKB)3710000000355374 035 $a(EBL)1964647 035 $a(SSID)ssj0001451877 035 $a(PQKBManifestationID)11759841 035 $a(PQKBTitleCode)TC0001451877 035 $a(PQKBWorkID)11478288 035 $a(PQKB)10146679 035 $a(DE-He213)978-3-319-10536-9 035 $a(MiAaPQ)EBC1964647 035 $a(PPN)184496535 035 $a(EXLCZ)993710000000355374 100 $a20150203d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDictionary of Corporate Social Responsibility $eCSR, Sustainability, Ethics and Governance /$fedited by Samuel O. Idowu, Nicholas Capaldi, Matthias S. Fifka, Liangrong Zu, René Schmidpeter 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (623 p.) 225 1 $aCSR, Sustainability, Ethics & Governance,$x2196-7075 300 $aDescription based upon print version of record. 311 $a3-319-10535-3 320 $aIncludes bibliographical references and index. 327 $aForewords -- Preface -- Introduction -- Contributors -- Keywords. 330 $aThis book is a concise and authoritative reference work and dictionary in the field of corporate social responsibility, sustainability, business ethics and corporate governance. It provides reliable definitions to more than 600 terms and concepts for researchers and professionals alike. By its definitions the dictionary helps users to understand the meanings of commonly used terms in CSR, and the roles and functions of CSR-related international organizations. Furthermore, it helps to identify keynotes on international guidelines, codes and principles relevant to CSR. The role of CSR in the business world has developed from a fig leaf marketing front into an important and indispensable aspect of corporate behavior over the past years. Sustainable strategies are valued, desired and deployed more and more by relevant players in business, politics, and societies all over the world. Both research and corporate practice therefore see CSR as a guiding principle for business success.  . 410 0$aCSR, Sustainability, Ethics & Governance,$x2196-7075 606 $aBusiness ethics 606 $aEthics 606 $aLeadership 606 $aRenewable energy resources 606 $aSustainable development 606 $aBusiness Ethics$3https://scigraph.springernature.com/ontologies/product-market-codes/526000 606 $aEthics$3https://scigraph.springernature.com/ontologies/product-market-codes/E14000 606 $aBusiness Strategy/Leadership$3https://scigraph.springernature.com/ontologies/product-market-codes/515010 606 $aRenewable and Green Energy$3https://scigraph.springernature.com/ontologies/product-market-codes/111000 606 $aSustainable Development$3https://scigraph.springernature.com/ontologies/product-market-codes/U34000 608 $aDictionaries.$2fast 615 0$aBusiness ethics. 615 0$aEthics. 615 0$aLeadership. 615 0$aRenewable energy resources. 615 0$aSustainable development. 615 14$aBusiness Ethics. 615 24$aEthics. 615 24$aBusiness Strategy/Leadership. 615 24$aRenewable and Green Energy. 615 24$aSustainable Development. 676 $a170 676 $a330 676 $a338.927 676 $a621.042 676 $a658.4092 676 $a658048 702 $aIdowu$b Samuel O$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aCapaldi$b Nicholas$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFifka$b Matthias S$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aZu$b Liangrong$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aSchmidpeter$b René$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298494303321 996 $aDictionary of Corporate Social Responsibility$92542201 997 $aUNINA LEADER 05606nam 2200781Ia 450 001 9910818381003321 005 20200520144314.0 010 $a9786612022067 010 $a9781282022065 010 $a1282022067 010 $a9780470187920 010 $a0470187921 010 $a9780470187913 010 $a0470187913 035 $a(CKB)1000000000376120 035 $a(EBL)427662 035 $a(OCoLC)476269799 035 $a(SSID)ssj0000141607 035 $a(PQKBManifestationID)11148635 035 $a(PQKBTitleCode)TC0000141607 035 $a(PQKBWorkID)10090175 035 $a(PQKB)10099530 035 $a(MiAaPQ)EBC427662 035 $a(Au-PeEL)EBL427662 035 $a(CaPaEBR)ebr10296311 035 $a(CaONFJC)MIL202206 035 $a(OCoLC)123332118 035 $a(FINmELB)ELB178943 035 $a(Perlego)2758591 035 $a(EXLCZ)991000000000376120 100 $a20070415d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug-drug interactions in pharmaceutical development /$fedited by Albert P. Li 205 $a1st ed. 210 $aHoboken, N.J. $cWiley-interscience$dc2008 215 $a1 online resource (261 p.) 225 1 $aWiley series in drug discovery and development 300 $aDescription based upon print version of record. 311 08$a9780471794417 311 08$a0471794414 320 $aIncludes bibliographical references and index. 327 $aDRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP) 327 $a1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways 327 $a1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding 327 $a2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions 327 $a2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References 327 $a3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development 330 $aDrug-Drug Interactions in Pharmaceutical Development comprehensively reviews the relevant science, industrial practice, and regulatory agency positions on drug-drug interactions. It focuses on the evaluation of potential drug-drug interactions, allowing researchers to address risk factors before a drug is put to market. The book covers both clinical and nonclinical aspects for understanding drug-drug interactions as well as in vitro and in vivo studies for use in studying interactions at the drug discovery stage. 410 0$aWiley series in drug discovery and development. 606 $aDrug interactions 606 $aDrug development 615 0$aDrug interactions. 615 0$aDrug development. 676 $a615.7045 676 $a615/.7045 676 $a615.7045 701 $aLi$b A. P$01616272 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910818381003321 996 $aDrug-drug interactions in pharmaceutical development$93946888 997 $aUNINA